Trebananib Completed Phase 2 Trials for Advanced Renal Cell Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00467025AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib